

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 45/06, 31/40, 31/19 // (A61K 31/40, 31:19) (A61K 31/40, 31:19, 31:135) (A61K 31/40, 31:19, 31:485)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/04808 (43) International Publication Date: 13 February 1997 (13.02.97)</p>
<p>(21) International Application Number: PCT/US96/12249 (22) International Filing Date: 25 July 1996 (25.07.96) (30) Priority Data: 08/508,775 28 July 1995 (28.07.95) US 08/611,528 5 March 1996 (05.03.96) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors: CRAMER, Ronald, Dean; 86 Oliver Road, Cincinnati, OH 45215 (US). MITRA, Sekhar; 7305 Demar Road, Cincinnati, OH 45243 (US). RIKER, Donald, Kay; 683 Deer Run Trail, Lebanon, OH 45036 (US). (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: COMPOSITIONS CONTAINING ANALGESICS AND ANTIHISTAMINES AND METHODS FOR TREATING RESPIRATORY DISORDERS</p> <p>(57) Abstract</p> <p>The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition comprising an analgesic agent along with certain pyrrolidine and piperidine ether antihistaminic agents.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOSITIONS CONTAINING ANALGESICS AND ANTIHISTAMINES AND METHODS FOR
TREATING RESPIRATORY DISORDERS

5

10

TECHNICAL FIELD

The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition comprising an analgesic agent along with certain pyrrolidine and piperidine ether antihistaminic agents.

BACKGROUND OF THE INVENTION

The common cold, although not usually a serious illness, is a highly prevalent, discomfoting and annoying affliction. The term "common cold" is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.

Early symptoms may be minimal with only mild malaise, sore throat and nasal complaints. With rhinovirus infection, symptoms of nasal discharge, nasal congestion, and sneezing usually commence on the first day of illness and progress to maximum severity by the second or third day. Along with nasal symptoms may come sore, dry or scratchy throat and hoarseness and cough. Other symptoms may include mild burning of the eyes, loss of smell and taste, a feeling of pressure or fullness in the sinuses or ears, headache, and vocal impairment. Fever can occur, but is uncommon. Influenza infection generally includes fever, often of sudden onset and persisting for several days, and with great severity; generalized aches and pains; fatigue and weakness; and chest discomfort.

At present, only symptomatic treatment is available for the common cold. The costs of treating colds with over-the-counter medications in the United States is estimated at an annual cost of over 1.5 billion dollars. The direct costs of treatment in outpatient clinics is estimated at almost four billion dollars. Indirect costs, based
5 on the amount of loss in wages because of restricted activity are substantially higher.

Exemplary prior art formulations for treatment of cough, cold, cold-like, allergy, sinus and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith generally contain an analgesic (aspirin or
10 acetaminophen) and one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.

The use of non-steroidal anti-inflammatory drugs to combat inflammation and attendant pain is accepted medical practice. The non-steroidals are commonly employed to relieve pain and inflammation associated with, for example, bursitis,
15 arthritis, headache and the like. Among the most commonly used drugs of the non-narcotic analgesic class of drugs are aspirin, acetaminophen, ibuprofen, ketoprofen, diclofenac and naproxen and their salts (e.g., lysine, arginine, sodium and potassium). Aspirin, acetaminophen and ibuprofen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold
20 multisymptom alleviating compositions. These commercially marketed products generally contain in addition to aspirin, acetaminophen or ibuprofen, one or more antihistaminics, decongestants, cough-suppressants, antitussives and expectorants.

The present inventors have found that selected compositions comprising an analgesic agent along with certain pyrrolidine and piperidine ether antihistaminic
25 agents provides improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms, including nasal congestion.

It is therefore an object of the present invention to provide a method for the treatment of cough, cold, cold-like, allergy, sinus and/or flu symptoms in a mammalian organism in need of such treatment comprising administering to such
30 organism the compositions of the present invention. Such symptoms as used herein refer to coryza, nasal congestion, sinus congestion, sinus pain, upper respiratory infections, otitis, sinusitis, etc.

SUMMARY OF THE INVENTION

The present invention relates to compositions and methods for providing
35 improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition

consisting essentially of an analgesic agent along with certain pyrrolidine and piperidine ether antihistaminic agents.

All percentages and ratios used herein are by weight unless otherwise indicated.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition consisting essentially of an analgesic agent along with certain pyrrolidine and piperidine ethers.

10 Analgesic Pharmaceutical Actives

Useful analgesic pharmaceutical actives in the compositions of the present invention include aspirin and acetaminophen as well as the non-steroidal anti-inflammatory drugs (NSAIDS) selected from the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are fully described in the U.S. Patent 4,985,459 to Sunshine et al., issued January 15, 1991, incorporated by reference herein. For detailed disclosure of the chemical structure, synthesis, side effects, etc., of non-steroidal anti-inflammatory agents, reference may be had to standard texts, including Anti-inflammatory and Anti-Rheumatic Drugs, K. D. Rainsford, Vol. I-III, CRC Press, Boca Raton, (1985), and Anti-inflammatory Agents, Chemistry and Pharmacology, 1, R. A. Scherrer, et al., Academic Press, New York (1974), both of which are incorporated by reference herein.

Useful dosage of these agents can be found in The Physicians' Desk Reference, 47th Edition (1993) and in U.S. Patent 4,552,899 to Sunshine et al. issued November 12, 1985, both of which are incorporated by reference herein.

Examples of preferred analgesic pharmaceutical actives useful in the present invention include, but are not limited to, acetaminophen, acetylsalicylic acid, ibuprofen, fenbuprofen, fenoprofen, flurbiprofen, indomethacin, ketoprofen, naproxen, their pharmaceutically-acceptable salts, enantiomers thereof, and mixtures thereof. Acetaminophen, ibuprofen and naproxen are especially preferred for use in the compositions of the present invention.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from nonorganic bases include sodium, potassium, lithium, ammonia, calcium, magnesium, ferrous, zinc, manganous, aluminum, ferric, manganic salts and the like. Salts derived from pharmaceutically acceptable organic non-toxic

bases include salts of primary, secondary, tertiary and quaternary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procaine, N-ethylpiperidine, 5 hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purines, piperazine, piperidine, polyamine resins and the like.


Most preferred for use herein is acetaminophen and the S(+) isomer of the NSAIDs and their salts. The term "S(+)" as applied to the analgesic agents herein is intended to encompass the dextrorotatory or S(+) isomer of the amino acid salt derivatives thereof. The expression "substantially free of the R(-) antipode" as used 10 in conjunction with the term "S(+)" means that the S(+) enantiomer is sufficiently free of its R(-) antipode to exert the desired onset-hastened and enhanced analgesic effect. Practically speaking, this means that the active ingredient should contain at least 90% by weight of the S(+) enantiomer and 10% or less weight R(-) 15 enantiomer. Preferably, the weight ratio of S(+) enantiomer to R(-) enantiomer is greater than 20:1, more preferably greater than 97:3. Most preferably the S(+) enantiomer is 99 or more % by weight free of R(-) enantiomer, i.e., the weight ratio of S to R is approximately equal to or greater than 99:1.

For example, the safe and effective amount of ibuprofen used in the compositions of the present invention generally ranges from about 50 to about 800 mg, 20 preferably from about 50 to about 400 mg and more preferably from about 50 to about 200 mg. The safe and effective amount of naproxen used in the compositions of the present invention generally ranges from about 50 to about 660 mg, preferably from about 100 to about 330 mg and more preferably from about 150 to 25 about 220 mg. The safe and effective amount of flurbiprofen used in the compositions of the present invention generally ranges from about 12.5 to about 300 mg, preferably from about 12.5 to about 200 mg, more preferably from about 12.5 to about 100 mg and most preferably from about 12.5 to about 50 mg. The safe and effective amount of ketoprofen used in the compositions of the present 30 invention generally ranges from about 5 to about 100 mg, preferably from about 5 to about 75 mg, more preferably from about 5 to about 50 mg and most preferably from about 5 to about 25 mg. Generally, the amount of the S(+) isomers of these agents will be about half of the amount of the racemic mixture.

Useful dosage of these agents can be found in The Physicians' Desk Reference, 47th Edition (1993) and in U.S. Patent 4,552,899 to Sunshine et al., issued 35 November 12, 1985, both of which are incorporated by reference herein.

Pyrrolidine and piperidine ether antihistaminic agents

The pyrrolidine and piperidine ethers are of the formula:



wherein R_1 is a radical selected from the group consisting of hydrogen, halogen, lower alkyl containing from 1 to 4 carbon atoms and lower alkoxy containing from 1 to 4 carbon atoms, R_2 is a radical selected from the group consisting of lower alkyl containing 1 to 4 carbon atoms, m is an integer from 0, 1, 2 and 3 and n is an integer from 1 to 2, with the proviso that $m+n$ must be at least 2. Salts of these compounds are also useful.

These compounds have antihistamine properties and are more fully described in U.S. Patent 3,097,212 to Jucker et al., issued July 9, 1963, incorporated by reference herein.

Preferred for use herein are N-methyl-2-[2'(α -methyl-p-chloro-benzhydryl-oxy)ethyl]-pyrrolidine and N-methyl-2-[2'(α -methyl-p-bromo-benzhydryl-oxy)ethyl]-pyrrolidine. Most preferred for use herein is N-methyl-2-[2'(α -methyl-p-chloro-benzhydryl-oxy)ethyl]-pyrrolidine which is commonly known as clemastine fumarate and sold as Tavist® by Sandoz Pharmaceuticals.

The safe and effective amount of these pyrrolidine and piperidine ethers generally ranges from about 0.1 to about 10 mg, preferably from about 0.3 to about 3 mg, more preferably from about 0.5 to about 2 mg and most preferably from about 0.67 to about 1.34 mg.

Additional Pharmaceutical Actives

The compositions of the present invention can also include at least one other pharmacological active selected from the following class: (a) a decongestant, (b) an expectorant (c) an additional antihistamine and (d) an antitussive. The decongestants useful in the compositions of the present invention include pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, their pharmaceutically acceptable salts, and mixtures thereof. The antitussives useful in the present invention include those such as dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, their pharmaceutically-acceptable salts, and mixtures thereof. The additional antihistamines useful in the present invention include those such as chlor-

pheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, azatadine, doxylamine, tripelemamine, cyproheptadine, hydroxyzine, carbinoxamine, phenindamine, bromodiphenhydramine, pyrilamine, their pharmaceutically acceptable salts, as well as the non-sedating antihistamines which include
5 acrivastine, AHR-11325, astemizole, azatadine, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, their pharmaceutically acceptable salts and mixtures thereof. The expectorants (also known as mucolytic agents) useful in the present invention include glyceryl guaiacolate, terpin hydrate, ammonium chloride,
10 N-acetylcysteine and bromhexine, ambroxol, their pharmaceutically acceptable salts, and mixtures thereof. All of these components, as well as their acceptable dosage ranges are described in the following: U.S. Patent 4,783,465 to Sunshine et al., issued November 8, 1988, U.S. Patent 4,619,934 to Sunshine et al., issued October 28, 1986, which are incorporated by reference herein.

15 Additional agents which are found useful in the present compositions are α -agonists such as those disclosed in U.S. Patent 5,478,858, issued December 26, 1995, incorporated herein by reference in its entirety.

Various oral dosage forms can be used, including such solid forms as tablets, caplets, capsules, granules, lozenges and bulk powders and liquid forms such as syrups and suspensions. Controlled release dosage forms which provide a controlled
20 release of these active(s) are also useful. These oral forms comprise a safe and effective amount, usually at least about 5% of the active components. Solid oral dosage forms preferably contain from about 5% to about 95%, more preferably from about 10% to about 95%, and most preferably from about 25% to about 95%
25 of the active components. Liquid oral dosage forms preferably contain from about 1% to about 50% and more preferably from about 1% to about 25% and most preferably from about 3% to about 10% of the active components.

Tablets can be compressed, triturated, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents,
30 disintegrating agents, coloring agents, flavoring agents, preservatives and flow-inducing agents. Also useful are soft gelatin capsules.

Liquid oral dosage forms include aqueous and nonaqueous solutions, emulsions, pseudo emulsions, suspensions, and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives,
35 emulsifying agents, suspending agents, diluents, sweeteners, taste-masking agents, coloring agents, and flavoring agents. Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms,

are described in U.S. Patent 3,903,297, Robert, issued September 2, 1975, incorporated by reference herein. Techniques and compositions for making solid oral dosage forms are described in Marshall, "Solid Oral Dosage Forms," Modern Pharmaceutics, Vol. 7, (Banker and Rhodes, editors), 359-427 (1979), incorporated by reference herein. Techniques and compositions for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are described in Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (1980), incorporated herein by reference.

An additional agent found useful in the present compositions is caffeine. Caffeine has been found to lessen the sedating effect of the pyrrolidine and piperidine ethers. The level of caffeine use is generally from about 20 mg to about 500 mg, preferably from about 50 mg to about 200 mg, most preferably from about 65 mg to about 100 mg.

In preparing the liquid oral dosage forms, the active component is incorporated into an aqueous-based orally acceptable pharmaceutical carrier consistent with conventional pharmaceutical practices. An "aqueous-based orally acceptable pharmaceutical carrier" is one wherein the entire or predominant solvent content is water. Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type. The most preferred carrier is a suspension of the pharmaceutical composition in an aqueous vehicle containing a suitable suspending agent. Suitable suspending agents include Avicel RC-591 (a microcrystalline-cellulose/sodium carboxymethyl cellulose mixture available from FMC), guar gum and the like. Such suspending agents are well known to those skilled in the art. While the amount of water in the compositions of this invention can vary over quite a wide range depending upon the total weight and volume of the active component and other optional non-active ingredients, the total water content, based on the weight of the final composition, will generally range from about 20 to about 75%, and, preferably, from about 20 to about 40%, by weight/volume.

Although water itself may make up the entire carrier, typical liquid formulations preferably contain a co-solvent, for example, propylene glycol, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients, such as flavoring oils and the like into the composition. In general, therefore, the compositions of this invention preferably contain from about 5 to about 25 volume/volume percent and, most preferably, from about 10 to about 25 volume/ volume percent, of the co-solvent.

Other optional ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final product, antioxidants, for example, butylated hydroxy anisole or butylated hydroxy toluene, and preservatives, for example, methyl or propyl paraben or sodium benzoate, to prolong and enhance shelf life. A highly preferred optional component is caffeine.

METHOD OF TREATMENT

The amount of the pharmaceutical composition administered depends upon the percent of active ingredients within its formula, which is a function of the amount of the naphthalene derivative and any optional components such as a decongestant, cough suppressant, expectorant and/or antihistamine required per dose, stability, release characteristics and other pharmaceutical parameters.

Usually from about 1 mg/kg to about 50 mg/kg per day, preferably from about 2 mg/kg to about 30 mg/kg per day and most preferably from about 3 mg/kg per day to about 20 mg/kg per day of the pharmaceutical composition is administered as described herein. This amount can be given in a single dose, or, preferably, in multiple (two to six) doses repeatedly or sustained release dosages over the course of treatment. Generally, each individual dosage of the pharmaceutical compositions of the present invention range from about 1 mg/kg to about 25 mg/kg, preferably from about 2 mg/kg to about 15 mg/kg and most preferably from about 3 mg/kg to about 10 mg/kg. While dosages higher than the foregoing are effective to provide relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms, care must be taken, as with any drug, in some individuals to prevent adverse side effects.

The following examples illustrate embodiments of the subject invention wherein both essential and optional ingredients are combined.

EXAMPLE I

A hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:

<u>Ingredient</u>	<u>Amount</u>
Ibuprofen	200.00 mg
Clemastine fumarate	0.67 mg
Pseudoephedrine HCl	30.00 mg
Triturate active ingredients and q.s. with lactose to selected capsule size.	

Administration of one or two the above capsules every four to twelve hours to a human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms.

EXAMPLE II

5 A hard compressed caplet composition for oral administration is prepared by combining the following ingredients:

	<u>Ingredient</u>	<u>Amount</u>
	Ibuprofen	300.00 mg
	Clemastine fumarate	0.67 mg
	Hydroxypropyl methylcellulose	300.00 mg
10	Corn starch	150.00 mg
	Pregelatinized starch	40.00 mg
	Silicon dioxide, colloidal	1.50 mg
	Stearic acid TP fine powder	2.00 mg
	Sodium lauryl sulfate	0.50 mg

15 Administration of two caplets every twelve hours to a human in need of treatment provides improved relief from cough, cold-like, flu-like and allergic rhinitis symptoms.

EXAMPLE III

20 A hard compressed tablet composition for oral administration is prepared by combining the following ingredients:

	<u>Ingredient</u>	<u>Amount</u>
	Naproxen sodium	220.00 mg
	Clemastine fumarate	1.34 mg
	Magnesium stearate	2.00 mg
25	Povidone	10.00 mg
	Talc	12.00 mg
	Microcrystalline cellulose	45.00 mg

Administration of one of the above tablets every twelve hours to a human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and
30 allergic rhinitis symptoms.

EXAMPLE IV

A liquid composition for oral administration is prepared by combining the following ingredients:

	<u>Ingredient</u>	<u>% W/V</u>
35	Naproxen sodium	2.2000
	Alcohol (95%)	25.0000
	Clemastine fumarate	0.0134

	Propylene Glycol	25.0000
	Sodium Citrate	2.0000
	Citric Acid	0.2500
	Liquid Sugar (Simple Syrup)	25.0000
5	Glycerin	7.0000
	Colorants	0.0080
	Flavor	0.5000
	Water, Purified QS	100.0000

The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, and actives other than naproxen sodium are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container. In a separate container the naproxen sodium is added to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.

Administration of 10 ml to 20 ml (2 to 4 teaspoonsful) every twelve hours to a human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms.

EXAMPLE V

A liquid composition for oral administration is prepared by combining the following ingredients:

25	<u>Ingredient</u>	<u>% W/V</u>
	Ibuprofen	2.0000
	Clemastine fumarate	0.0067
	Alcohol (95%)	25.0000
	Propylene Glycol	25.0000
30	Sodium Citrate	2.0000
	Citric Acid	0.2500
	Liquid Sugar (Simple Syrup)	25.0000
	Glycerin	7.0000
	Colorants	0.0080
35	Flavor	0.5000
	Water, Purified QS	100.0000

The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, clemastine fumarate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container. In a separate container the ibuprofen is added to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.

Administration of 10 ml to 20 ml (2 to 4 teaspoonsful) every four to twelve hours to a human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms.

EXAMPLE VI

A liquid composition for oral administration is prepared by combining the following ingredients:

	<u>Ingredient</u>	<u>% W/V</u>
	S(+) Ibuprofen Lysinate	2.000
	Clemastine fumarate	0.009
20	Dextromethorphan HBr	0.300
	Alcohol (95%)	25.000
	Propylene Glycol	25.000
	Sodium Citrate	2.000
	Citric Acid	0.250
25	Liquid Sugar (Simple Syrup)	25.000
	Glycerin	7.000
	Colorants	0.008
	Flavor	0.500
	Water, Purified QS	100.000


The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid and clemastine fumarate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container. In a separate container the S (+) ibuprofen lysinate and dextromethorphan HBr are added sequentially to the alcohol while stirring.

The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.

Administration of 20 ml (4 teaspoonsful) every eight to twelve hours to a
5 human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms.

WHAT IS CLAIMED IS:

1. A composition for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition consisting essentially of:
 - (a) an analgesic pharmaceutical active; and
 - (b) a pyrrolidine or piperidine ether antihistaminic agent of the formula:



wherein R_1 is a radical selected from the group consisting of hydrogen, halogen, lower alkyl containing from 1 to 4 carbon atoms and lower alkoxy containing from 1 to 4 carbon atoms, R_2 is a radical selected from the group consisting of lower alkyl containing 1 to 4 carbon atoms, m is an integer from 0, 1, 2 and 3 and n is an integer from 1 to 2, with the proviso that $m+n$ must be at least 2.

2. A pharmaceutical composition according to Claim 1 wherein said antihistaminic agent is selected from the group consisting of N-methyl-2-[2'(α -methyl-p-chloro-benzhydryl-oxy)ethyl]-pyrrolidine and N-methyl-2-[2'(α -methyl-p-bromo-benzhydryl-oxy)ethyl]-pyrrolidine and salts thereof.
3. A pharmaceutical composition according to either of Claims 1 or 2 wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofen and diclofenac.
4. A pharmaceutical composition according to any of the above Claims wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, flurbiprofen, and ketoprofen.

5. A pharmaceutical composition according to any of the above Claims wherein said antihistaminic agent is N-methyl-2-[2'(α -methyl-p-chloro-benzhydryl-oxy)ethyl]-pyrrolidine.
6. A pharmaceutical composition according to any of the above Claims wherein said propionic acid derivative is the amino acid salt and is selected from the group consisting of triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, ornithine, arginine, histidine, caffeine, procaine, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purine, piperazine and piperidine and mixtures thereof.
7. A pharmaceutical composition according to any of the above Claims which also contains an additional pharmaceutical active selected from the group consisting of decongestants, expectorants, additional antihistamines and antitussives.
8. A pharmaceutical composition according to any of the above Claims wherein said decongestant is pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, mixtures thereof or pharmaceutically acceptable salts thereof.
9. A pharmaceutical composition according to any of the above Claims wherein said antitussive is selected from the group consisting of dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, mixtures thereof or pharmaceutically acceptable salts thereof.
10. A pharmaceutical composition according to any of the above Claims wherein said expectorant is an expectorant or mucolytic such as glyceryl guaiacolate, terpin hydrate, ammonium chloride, N-acetylcysteine, bromhexine and ambroxol, mixtures thereof or pharmaceutically acceptable salts thereof.
11. A pharmaceutical composition according to any of the above Claims wherein said additional antihistamine is selected from the group consisting of

chlorpheniramine, brompheniramine, dexchlorpheniramine, dextbrompheniramine, triprolidine, doxylamine, tripelemine, cyproheptadine, carbinoxamine, bromodiphenhydramine, pyrilamine, acrivastine, AHR-11325, phenindamine, astemizole, azatadine, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, mixtures thereof or pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition according to any of the above Claims which comprises the S(+) enantiomer of the propionic acid nonsteroidal anti-inflammatory agent.
13. A pharmaceutical composition according to any of the above Claims wherein said S(+) enantiomer is selected from the group consisting of S(+)-ketoprofen lysinate, S(+)-ibuprofen lysinate, and S(+)-naproxen lysinate.
14. A pharmaceutical composition according to any of the above Claims which in addition contains an α -agonist compound.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/12249

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K45/06 A61K31/40 A61K31/19 //(A61K31/40,31:19),
(A61K31/40,31:19,31:135), (A61K31/40,31:19,31:485)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	EP,A,0 130 690 (TEIJIN LTD) 9 January 1985 see page 7, line 29 - page 8, line 4; examples 7,9 ---	1-5,11 1-5,7-13
Y	WO,A,94 14449 (PROCTER & GAMBLE) 7 July 1994 see page 4, line 17-26; example 5 see page 7, line 23 - page 8, line 2 see claims 1-7; examples 2,4 ---	1-5,7-13
Y	WO,A,92 05783 (MERCK & CO INC) 16 April 1992 see page 2, line 12 - page 3, line 27 see page 5, line 2-4; examples 1-6 see page 7, line 5-29; claims 1-3,5,6,8 --- -/--	1-5, 11-13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 December 1996

Date of mailing of the international search report

10.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/12249

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,85 04589 (SUNSHINE ABRAHAM) 24 October 1985 see page 2, line 9 - page 3, line 6 see page 7, line 30 - page 8, line 2 see claims 1-4,6,14-20; examples 2,3; table 1 ---	3-11
A	WO,A,93 09764 (INNOVATIVE TECH CENTER) 27 May 1993 see page 6, line 17-20 see page 16, line 10-16 see page 22, line 23-26; claims 16-19 see page 24, line 9-11; claims 1,2,4-9 see page 24, line 29 - page 25, line 6 ---	3,4,6, 11,14
A	WO,A,94 09767 (SMITHKLINE BEECHAM PLC) 11 May 1994 see page 3, line 10 - page 4, line 35; claims 3-10 -----	1-5,7-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/12249

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-130690	09-01-85	JP-C- 1814575	18-01-94
		JP-B- 3015606	01-03-91
		JP-A- 59222406	14-12-84
		DE-A- 3485075	24-10-91
		US-A- 4569837	11-02-86

WO-A-9414449	07-07-94	AU-B- 672279	26-09-96
		AU-A- 5899394	19-07-94
		CA-A- 2149317	07-07-94
		CN-A- 1094615	09-11-94
		EP-A- 0674517	04-10-95
		JP-T- 8504818	28-05-96

WO-A-9205783	16-04-92	AU-A- 8764191	28-04-92
		CA-A- 2092566	29-03-92
		EP-A- 0550668	14-07-93
		JP-T- 6502166	10-03-94

WO-A-8504589	24-10-85	US-A- 4552899	12-11-85
		AU-A- 2029195	03-08-95
		AU-B- 589554	19-10-89
		AU-A- 4120085	01-11-85
		CA-A- 1258430	15-08-89
		DE-A- 3585495	09-04-92
		EP-A- 0180597	14-05-86
		JP-T- 61501913	04-09-86
		US-A- 4749697	07-06-88
		US-A- 4839354	13-06-89
		US-A- 4749722	07-06-88
		US-A- 4749711	07-06-88
		US-A- 4749723	07-06-88
		US-A- 4749720	07-06-88
		US-A- 4749721	07-06-88
		US-A- 4783465	08-11-88
		US-A- 4920149	24-04-90
		US-A- 4840962	20-06-89
		US-A- 4871733	03-10-89
		US-A- 5025019	18-06-91
		US-A- 4619934	28-10-86
		US-A- 4738966	19-04-88

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/12249

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9309764	27-05-93	US-A- 5240694	31-08-93
		CA-A- 2122719	27-05-93
		EP-A- 0661967	12-07-95
		JP-T- 8508007	27-08-96
		US-A- 5422097	06-06-95
		US-A- 5492689	20-02-96

WO-A-9409767	11-05-94	NONE	
